SOURCINGLINK.NET, INC.

Ajouter à une liste

Instrument Inactif

Communiqués SourcingLink.net, Inc. OTC Bulletin Board

Actions

US8361714053

Produits pharmaceutiques

Communiqués

12/07/22	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
29/06/22	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
06/06/22	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
14/02/22	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
14/02/22	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU
20/07/21	Oncology Pharma Inc :.	AQ
31/03/21	Oncology Pharma : Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities	AQ
16/03/21	Oncology Pharma : Reveals Strategic Plans for Company Growth and Focus	AQ
10/03/21	Oncology Pharma : Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	AQ
04/03/21	Oncology Pharma : Moves to Fund Lead Drug Formulation & IND-Enabling Studies	AQ
26/02/21	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	GL
22/02/21	Oncology Pharma : Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology	AQ
16/02/21	Oncology Pharma : is Pleased to Welcome New Chairman to Its Scientific Advisory Board	AQ
09/02/21	Oncology Pharma : Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform	AQ
03/02/21	Oncology Pharma : Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology	AQ
29/01/21	Oncology Pharma Announces the Appointment Of New Chief Financial Officer	GL
27/08/20	Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Espace mes listes

Palmarès

Suite du Palmarès

Palmarès

Suite du Palmarès

Devises / Forex

Matières Premières

Cryptomonnaies

Taux d'Intérêts

Google vous laisse choisir vos sources.

G Google

Choisissez Zonebourse

G Google

Choisissez Zonebourse